Our 2017 Cancer Immunotherapy 2.0 report featured in Drug Development & Delivery

  Drug Development and Delivery published an article based on our 2017 report on Cancer Immunotherapy 2.0 in its November/December 2017 issue. To see the article, please go to http://www.drug-dev.com/Main/Back-Issues/CANCER-IMMUNOTHERAPY-Building-on-Initial-Successes-1402.aspx To order our report, Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes, please see the CHI Insight Pharma Reports website. ______________________________________________________________________________________________________________________________________________ As the…

Can immunotherapy 2.0 strategies save the cancer vaccine field?

  On September 15, 2017, Bavarian Nordic’s Phase 3 trial of its cancer vaccine Prostvac ended in failure. Prostvac failed to improve overall survival in patients with metastatic castration-resistant prostate cancer, as determined by the clinical trial. We had listed Prostvac in Chapter 5 and in Table 5-2 of our 2017 report, Cancer Immunotherapy: Building…

How immunotherapy 2.0 has been shaping corporate acquisition strategy: the Merck-Rigontec deal

  As noted in our 2017 Insight Pharma Report, “Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes” the most successful class of immunotherapeutics continues to be that of the checkpoint inhibitors (discussed in Chapter 2 of our report). Immune checkpoints refer to a large number of inhibitory pathways in the immune system, especially…

New perspectives in commercialization of cellular immunotherapies for cancer

  Late stage cellular immunotherapy products for treatment of hematologic tumors In the field of commercialization of cellular immunotherapy for cancer, all eyes have been on two chimeric antigen receptor (CAR) T-cell therapies (from Novartis and Kite Pharma), which have been in preregistration with the FDA as of March 2017. We discussed the field of…

New Report Published By CHI Insight Pharma Reports Highlights Progress in Cancer Immunotherapy

On May 3, 2017 Cambridge Healthtech Institute’s (CHI’s) Insight Pharma Reports announced the publication of a new book-length report, Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes, by Allan B. Haberman, Ph.D. The new 2017 report includes an updated discussion of approved and clinical stage agents in immuno-oncology. It also addresses the means…